Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 18/20 | 0.49 |
| ▸ | PPARG | P37231 | 13/20 | 0.47 |
| ▸ | PPARD | Q03181 | 9/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251360 | 1.00 | PPARA (0.49) | PPARAPPARGPPARD | |
| SCHEMBL3966545 | 0.92 | PPARA (0.39) | PPARAPPARGPPARD | |
| SCHEMBL3961357 | 0.87 | PPARA (0.47) | PPARAPPARGPPARD | |
| SCHEMBL5976535 | 0.83 | PPARA (0.53) | PPARAPPARGPPARD | |
| SCHEMBL3966547 | 0.82 | FFAR1 (0.42) | — | |
| SCHEMBL3964391 | 0.82 | PPARA (0.59) | PPARAPPARGPPARD | |
| SCHEMBL3960482 | 0.82 | PPARA (0.54) | PPARAPPARGPPARD | |
| SCHEMBL3963119 | 0.82 | PPARA (0.59) | PPARAPPARGPPARD | |
| SCHEMBL6049558 | 0.82 | PPARA (0.59) | PPARAPPARGPPARD | |
| SCHEMBL5975824 | 0.82 | PPARA (0.54) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256307-B2 | Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor α(PPAR) | ASTRAZENECA AB (SE) | 2007-08-14 | — | — | US | claimed |
| EP-1458672-B1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA(PPAR) | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | claimed |
| US-20050113362-A1 | Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) | ASTRAZENECA AB R & D HEADQUARTERS - GLOBAL IINTELLECTUAL PROPERT (SE) | 2005-05-26 | — | — | US | claimed |
| EP-1458672-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA(PPAR) | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | claimed |
| WO-2003051822-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR) | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | claimed |
| US-7488844-B2 | Therapeutic agents | ASTRAZENECA AB (SE) | 2009-02-10 | — | — | US | disclosed |
| US-7256307-B2 | Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor α(PPAR) | ASTRAZENECA AB (SE) | 2007-08-14 | — | — | US | disclosed |
| EP-1458672-B1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA(PPAR) | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| US-20050282822-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | disclosed |
| US-20050113362-A1 | Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) | ASTRAZENECA AB R & D HEADQUARTERS - GLOBAL IINTELLECTUAL PROPERT (SE) | 2005-05-26 | — | — | US | disclosed |
| EP-1458672-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA(PPAR) | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051822-A1 | SUBSTITUTED PHENYLPROPIONIC ACID DERIVATIVES AS AGONISTS TO HUMAN PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA (PPAR) | ASTRAZENECA AB (SE) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282822-A1 | Therapeutic agents | GPR119, LIPC, PNLIP | PPARA 346/4885PPARG 228/4885PPARD 623/4885 |
| US-20050113362-A1 | Substituted phenypropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha (ppar) | PPARA, PPARD, PPARG | PPARA 1/4885PPARG 3/4885PPARD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.